Antihistamines could be promising adjuvant therapy for Parkinson’s disease
Click Here to Manage Email Alerts
CHICAGO — A literature-based discovery machine learning algorithm suggested that antihistamines could be adjuvants to levodopa for Parkinson’s disease, a poster showed at the 2022 American Neurological Association annual meeting.
Gabriella Tandra, BS, and Amy Yoone, BS, both of the Georgia Institute of Technology, used SemNet 2.0, a literature-based discovery software tool, to curate more than 30 million PubMed articles and identify potential adjuvants for PD treatment.
“We did this with the purpose of trying to find drugs that we could repurpose for the treatment of Parkinson’s disease or use as adjuvants to levodopa,” Tandra told Healio.
After running simulations that compared the relatedness of key words to dopamine and levodopa, “we found that antihistamines were recurring,” Yoone told Healio.
“After doing some research and finding articles to support antihistamine [use], we concluded that it could be a promising adjuvant therapy for Parkinson’s.”